FDA OK's American Bio Medica's drug test:
This article was originally published in Clinica
Executive Summary
American Bio Medica has gained FDA 510(k) clearance to sell in the US its point-of-care Rapid Tec 5 test, which can detect five classes of commonly abused illicit drugs from a single urine sample, says the company. The device, which provides qualitative identification of THC (tetrahydrocannabinol), cocaine, PCP (phencyclidine), opiates and amphetamines, uses just a single test strip and as such is less expensive than other multiple drug screening devices, says the Kinderhook, New York firm. Sun Biomedical has also recently announced that it is developing a saliva drug test (see Clinica No 1019, p 19).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.